WallStreetZenWallStreetZen

NASDAQ: SLN
Silence Therapeutics PLC Stock

Open Broker Account
$17.09+0.09 (+0.53%)
Updated Dec 5, 2022
SLN Price
$17.09
Fair Value Price
$19.82
Market Cap
$511.14M
52 Week Low
$7.80
52 Week High
$26.35
P/E
N/A
P/B
12.88x
P/S
16x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.78M
Earnings
-$42.05M
Gross Margin
43.9%
Operating Margin
-269.63%
Profit Margin
-223.9%
Debt to Equity
N/A
Operating Cash Flow
-$40M
Beta
0.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SLN Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SLN ($17.09) is undervalued by 13.8% relative to our estimate of its Fair Value price of $19.82 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SLN ($17.09) is not significantly undervalued (13.8%) relative to our estimate of its Fair Value price of $19.82 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more SLN due diligence checks available for Premium users.

Be the first to know about important SLN news, forecast changes, insider trades & much more!

SLN News

Valuation

SLN fair value

Fair Value of SLN stock based on Discounted Cash Flow (DCF)
Price
$17.09
Fair Value
$19.82
Undervalued by
13.80%
SLN ($17.09) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLN ($17.09) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

SLN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
12.88x
Industry
4.96x
SLN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SLN's financial health

Profit margin

Revenue
$3.9M
Net Income
-$8.3M
Profit Margin
-210.7%
SLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SLN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$144.2M
Liabilities
$0.0
Debt to equity
0
SLN's short-term assets ($131.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials

Cash flow

Operating
-$10.9M
Investing
-$48.8k
Financing
$50.1M
SLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SLN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SLN$511.14M+0.53%N/A12.88x
AVEO$518.32M-0.07%-18.18x17.97x
CHRS$524.22M-2.74%-1.88x-5.40x
BTAI$524.88M+3.31%-3.84x4.13x
RAPT$494.43M-6.08%-6.48x2.61x

Silence Therapeutics Stock FAQ

What is Silence Therapeutics's quote symbol?

NASDAQ: SLN) Silence Therapeutics trades on the NASDAQ under the ticker symbol SLN. Silence Therapeutics stock quotes can also be displayed as NASDAQ: SLN.

If you're new to stock investing, here's how to buy Silence Therapeutics stock.

What is the 52 week high and low for Silence Therapeutics (NASDAQ: SLN)?

(NASDAQ: SLN) Silence Therapeutics's 52-week high was $26.35, and its 52-week low was $7.80. It is currently -35.14% from its 52-week high and 119.1% from its 52-week low.

How much is Silence Therapeutics stock worth today?

(NASDAQ: SLN) Silence Therapeutics currently has 89,815,213 outstanding shares. With Silence Therapeutics stock trading at $17.09 per share, the total value of Silence Therapeutics stock (market capitalization) is $511.14M.

Silence Therapeutics stock was originally listed at a price of $19.50 in Sep 8, 2020. If you had invested in Silence Therapeutics stock at $19.50, your return over the last 2 years would have been -12.36%, for an annualized return of -6.38% (not including any dividends or dividend reinvestments).

How much is Silence Therapeutics's stock price per share?

(NASDAQ: SLN) Silence Therapeutics stock price per share is $17.09 today (as of Dec 5, 2022).

What is Silence Therapeutics's Market Cap?

(NASDAQ: SLN) Silence Therapeutics's market cap is $511.14M, as of Dec 6, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Silence Therapeutics's market cap is calculated by multiplying SLN's current stock price of $17.09 by SLN's total outstanding shares of 89,815,213.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.